SURVYR

HR

Healthcare Realty Trust Incorporated
$17.53
−$0.36 (2.01%)Oct 28 close
Real EstateS&P 400 CompareTechnicals
Model valuationLooks expensiveDCF base $9
1M3M6M1Y2Y
-11%-2%+6%+15%+24%Oct 2025Oct 2026Apr 202652w high $22.0452w low $16.31
HRSPY
Wall St. Highest PT $24.00 (+36.9%) Wall St. Avg PT $21.08 (+20.3%)
$16$18$21$24$26POC $17Hi $24Avg $21
Underwater Drawdown %Max DD -21.9%Current -18.9%
0.0%-21.9%
Relative Strength vs SPY-15.1% vs SPYUnderperforming
+22%0%-22%
1W
+$0.29 (1.68%)
1M
−$0.45 (2.50%)
3M
−$4.01 (18.63%)
6M
−$0.49 (2.70%)
YTD
+$1.20 (7.36%)
1Y
+$0.49 (2.85%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
13 analysts · mean score 2.38
1 = Strong Buy · 5 = Sell
Strong Buy215%
Buy323%
Hold862%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$17.53
Average target$21.08
+$3.55 (+20.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$18.00
Median$21.50
High$24.00
12-month Wall Street target range
Recent analyst rating changes · 30
Upgrade
2026-10-20 · Deutsche Bank upgraded HR from Hold to Buy
Reiterated
2026-10-19 · Wells Fargo reiterated Equal-Weight on HR
Reiterated
2026-10-13 · UBS reiterated Neutral on HR
Reiterated
2026-09-01 · Wells Fargo reiterated Equal-Weight on HR
Reiterated
2026-08-07 · RBC Capital reiterated Sector Perform on HR
Reiterated
2026-07-31 · Cantor Fitzgerald reiterated Overweight on HR
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Distress zone
Altman Z-score 0.8
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Average
Piotroski F-score 6 of 9
See the tests
  • ✗Positive net income
  • ✓Positive operating cash flow
  • ✓Return on assets improved
  • ✓Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✗Current ratio improved
  • ✓No share dilution
  • ✗Gross margin improved
  • ✓Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$6.2B
P/E (next 12 months, estimated)447.2
52-week range$16.31 – $22.04
Revenue growth (latest quarter vs a year ago)-4.3%
Dividend yield5.37%
Analyst consensusBuy (12)
Average analyst price target$21.08 (+20%)

What they do

Healthcare Realty Trust Incorporated is a real estate investment trust (REIT) that owns and operates medical outpatient buildings primarily located around market-leading hospital campuses. The Company selectively grows its portfolio through property acquisition and development. Healthcare Realty Trust Incorporated was incorporated in 1992 and is based in Nashville, United States.

Real Estate · REIT - Healthcare Facilities
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Looks expensive
Model read-out from the numbers below, not advice. Score -4 (DCF counts double).
▼DCF (base case)below the price by 48%
▼Forward P/E vs sector447.2x vs median 30.8x
•Piotroski F-score6/9
▼Altman Z0.8 (distress)
▼Net debt / EBITDA6.2x
▲Analyst target+20% (12 analysts)

Discounted cash flow

Bear
$1
-93%
growth -3% · disc. 9.4% · term. 2.0%
Base
$9
-48%
growth 2% · disc. 8.4% · term. 2.5%
Bull
$21
+19%
growth 5% · disc. 7.4% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Today's price assumes free cash flow grows about 6% a year for 10 years.
Implied
+6%/yr
FCF, last 3 yrs
+19%/yr
FCF, last 5 yrs
-1%/yr
Revenue, last 3 yrs
+8%/yr
Revenue, last 5 yrs
+19%/yr
Same inputs as the DCF above: trailing free cash flow 0.4B, 8.4% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.84 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Real Estate

P/E (trailing)
sector median 28.9×
 –
Forward P/E
sector median 30.8× · 98th pct
 447.2×
pricier
EV / EBITDA
sector median 17.3× · 34th pct
 15.5×
cheaper
Price / sales
sector median 6.6× · 38th pct
 5.4×
cheaper
Price / book
sector median 1.8× · 37th pct
 1.5×
cheaper
FCF yield
sector median 6.8% · 57th pct
 7.1%
cheaper

Forward EPS $0.04 vs trailing $-0.26. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
12.6%
FCF margin
38.5%
Net margin
-7.6%
Return on equity
-2.1%
Return on invested capital
1.4%
Net debt / EBITDA
6.2×
Current ratio
–
Interest cover
0.8×
Cash conversion (OCF/NI)
–
Piotroski F-score 6/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Altman Z-score 0.8 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$21
+20%
Analysts
12
Buy
Range
$18–$24
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$1.2B$-246.1M$457.1M
2024$1.3B$-654.5M$501.6M
2023$1.3B$-278.3M$499.8M
2022$932.6M$40.9M$272.7M
2021$534.8M$66.7M$232.6M
2020$499.6M$72.2M$470.1M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +8.2%.

For information only · Important disclosures

Grades vs sector

Momentum
47th percentile in sector
C
12-1 return: +5.3%
Percentile within its GICS sector across the S&P 1500.
Growth
6th percentile in sector
F
Revenue growth (YoY): -4.3%
Percentile within its GICS sector across the S&P 1500.
Value
38th percentile in sector
C-
Forward E/P: 0.3% · EBITDA/EV: 6.7%
Percentile within its GICS sector across the S&P 1500.
Profitability
9th percentile in sector
D-
Profit margin: -7.6% · Return on equity: -1.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

HR earningsReports tomorrow
Next report · quarter Sep 2026
Thu Oct 29, 2026After the close
EPS consensus$0.00 range $0.00–$0.00
Revenue consensus$283.5M 2 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$0.13est -$0.02−691.7%Below estimates
Feb 12, 2026-$0.03est -$0.03−10.3%In line with estimates
Oct 30, 2025-$0.06est -$0.07+15.4%Above estimates
Jul 31, 2025-$0.08est -$0.09+11.4%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-28 07:05:47 ET
24-0824-1025-0225-0525-0725-1026-0226-07-0.160.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$281.8M-5.3%
2026-03-31$279.0M–
2025-12-31$258.1M–
2025-09-30$297.8M–
2025-06-30$297.5M–

Recent dividends

2026-08-11: $0.240 · 2026-05-11: $0.240 · 2026-02-24: $0.240 · 2025-11-10: $0.240 · 2025-08-14: $0.240 · 2025-05-12: $0.310 · 2025-03-03: $0.310 · 2024-11-12: $0.310

News & catalysts

More news
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
24/7 Wall St. · Oct 20
Rating changes
Upgrade
2026-10-20 · Deutsche Bank upgraded HR from Hold to Buy
Reiterated
2026-10-19 · Wells Fargo reiterated Equal-Weight on HR
Reiterated
2026-10-13 · UBS reiterated Neutral on HR
Reiterated
2026-09-01 · Wells Fargo reiterated Equal-Weight on HR
Reiterated
2026-08-07 · RBC Capital reiterated Sector Perform on HR
Reiterated
2026-07-31 · Cantor Fitzgerald reiterated Overweight on HR

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Hull Robert E
EVP and COO · 2026-09-08
Sell
$401.3K

Stats refreshed 2026-10-28 07:05:47 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026